Your browser is no longer supported. Please, upgrade your browser.
Index- P/E- EPS (ttm)-2.70 Insider Own13.93% Shs Outstand17.72M Perf Week2.92%
Market Cap116.20M Forward P/E- EPS next Y-3.19 Insider Trans121.97% Shs Float6.24M Perf Month-2.76%
Income-47.40M PEG- EPS next Q-0.85 Inst Own50.00% Short Float1.82% Perf Quarter-44.63%
Sales- P/S- EPS this Y-149.70% Inst Trans-0.59% Short Ratio0.42 Perf Half Y-54.07%
Book/sh3.67 P/B1.15 EPS next Y-2.30% ROA-54.90% Target Price- Perf Year-81.30%
Cash/sh2.43 P/C1.74 EPS next 5Y- ROE-59.30% 52W Range4.05 - 29.92 Perf YTD-80.82%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.93% Beta-
Dividend %- Quick Ratio10.20 Sales past 5Y- Gross Margin- 52W Low3.95% ATR0.28
Employees27 Current Ratio10.20 Sales Q/Q- Oper. Margin- RSI (14)40.09 Volatility6.43% 6.07%
OptionableYes Debt/Eq0.00 EPS Q/Q-25.20% Profit Margin- Rel Volume0.10 Prev Close4.23
ShortableYes LT Debt/Eq0.00 EarningsAug 06 BMO Payout- Avg Volume272.75K Price4.21
Recom1.70 SMA20-6.91% SMA50-16.14% SMA200-58.15% Volume9,181 Change-0.47%
Aug-11-21Downgrade Morgan Stanley Overweight → Equal-Weight $33 → $12
May-12-21Resumed Citigroup Buy $30
Aug-17-20Upgrade Citigroup Neutral → Buy $34 → $30
Jun-30-20Downgrade Citigroup Buy → Neutral $30 → $34
Apr-06-20Initiated SVB Leerink Outperform $25
Apr-06-20Initiated Morgan Stanley Overweight $35
Apr-06-20Initiated Cowen Outperform $25
Sep-15-21 07:00AM  
Sep-06-21 08:08AM  
Sep-03-21 07:00AM  
Aug-06-21 07:00AM  
Aug-05-21 07:15AM  
Aug-02-21 06:07PM  
Jul-30-21 07:00AM  
Jul-14-21 06:59AM  
Jul-13-21 10:58PM  
Jun-30-21 07:00AM  
Jun-23-21 02:58PM  
Jun-17-21 07:00AM  
Jun-11-21 03:00AM  
Jun-08-21 04:41AM  
Jun-04-21 07:00AM  
May-11-21 07:00AM  
May-04-21 07:00AM  
Mar-29-21 07:00AM  
Mar-22-21 04:05PM  
Mar-17-21 07:00AM  
Mar-15-21 11:00AM  
Mar-14-21 08:16PM  
Mar-12-21 05:45AM  
Mar-10-21 02:40AM  
Mar-05-21 07:00AM  
Feb-26-21 09:30PM  
Feb-19-21 07:00AM  
Jan-20-21 07:00AM  
Jan-06-21 05:21PM  
Dec-10-20 01:01AM  
Dec-07-20 07:00AM  
Nov-30-20 10:36PM  
Nov-17-20 07:00AM  
Nov-05-20 07:00AM  
Oct-31-20 08:00AM  
Oct-29-20 07:00AM  
Oct-16-20 07:00AM  
Sep-02-20 07:00AM  
Aug-25-20 07:00AM  
Aug-14-20 08:26AM  
Aug-13-20 04:01PM  
Aug-07-20 07:00AM  
Jul-30-20 07:00AM  
Jun-29-20 04:01PM  
Jun-25-20 07:00AM  
Jun-24-20 07:00AM  
Jun-22-20 01:57PM  
Jun-13-20 08:44AM  
Jun-12-20 07:46AM  
May-21-20 07:00AM  
May-07-20 07:00AM  
May-06-20 07:00AM  
May-04-20 07:00AM  
Apr-23-20 07:00AM  
Mar-11-20 09:57PM  
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and -thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORBIMED ADVISORS LLCDirectorJul 16Buy6.001,666,6669,999,9961,666,666Jul 16 04:27 PM
Bonita David PDirectorJul 16Buy6.001,666,6669,999,9961,666,666Jul 16 04:21 PM
Chin MarkDirectorJul 16Buy6.001,333,3337,999,9982,344,072Jul 28 08:50 AM
Ballal Rahul D.Chief Executive OfficerDec 17Option Exercise3.154,99915,7474,999Dec 21 04:47 PM
Ballal Rahul D.Chief Executive OfficerDec 17Sale25.004,999124,9750Dec 21 04:47 PM
GRAY MICHAELCFO & COODec 11Option Exercise4.921,2506,1501,250Dec 15 04:26 PM
GRAY MICHAELCFO & COODec 11Sale25.001,25031,2500Dec 15 04:26 PM